In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...

The U.S. Food and Drug Administration has placed a clinical hold on Intellia Therapeutics' two late-stage trials testing an ...

A 3-year-old girl who underwent a breakthrough gene therapy treatment to treat profound hearing loss can hear on her own, two ...

The FDA has officially placed two of Intellia’s Phase III studies under clinical hold after the biotech reported earlier this ...

The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

A one-time gene therapy using a patient’s own stem cells has effectively cured a deadly immune disorder in 95% of treated ...

Duke Eye Center has become the first academic medical center in the country to implant a new cell-based gene therapy for a ...

For children born with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), an investigational ...

FDA moves to speed biosimilar approvals by eliminating comparative studies, aiming to lower drug costs and increase ...

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...